HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $58 price target.
May 09, 2024 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Mirum Pharmaceuticals with a $58 price target.
The reiteration of a Buy rating and maintenance of a $58 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term price movement for MIRM. Analyst ratings and price targets are significant indicators for investors, and a positive outlook from a well-regarded analyst can influence market perception and investor sentiment towards the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100